← All stocks

LENZ Therapeutics, Inc.

LENZ Net selling

CIK 0001815776 #4144 in the set updated 18 Sep 2026

Bought (12 mo)

$654.87K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$16.33M

$0.00 on a plan · $261.02K straight out of an exercise

Sold at will

$16.07M

12 of 14 sales

Net

−$15.67M

−$15.41M against sales at will

By person

6 insiders · 20 transactions

0.9×

Evert Schimmelpennink holds only 0.9 times base salary in stock. $662.37K of shares against $690.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Evert Schimmelpennink last reported holding, valued at $8.57, the price Common Stock was last bought or sold at on the open market here, on 27 Mar 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Versant Venture Capital VI, L.P. entity

10% owner

—

$16.07M (12)

−$16.07M

1,814,726

5.78%

$15.55M

−51.0%

Olsson Shawn

Chief Commercial Officer

—

$261.02K (2) scheduled

−$261.02K

4,733

0.0151%

$40.56K

—

Schimmelpennink Evert B.

President, CEO and Secretary

$251.41K (1)

—

+$251.41K

77,289

0.2460%

$662.37K

+71.8%

MCCOLLUM JAMES W

Director

$239.28K (1)

—

+$239.28K

10,500

0.0334%

$89.99K

—

Chevallard Daniel R.

Chief Financial Officer

$114.29K (3)

—

+$114.29K

12,886

0.0410%

$110.43K

+304.2%

George Jeffrey P.

Director

$49.89K (1)

—

+$49.89K

5,592

0.0178%

$47.92K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Chevallard Daniel R.

27 Mar 2026

Chief Financial Officer

Buy

7,500

$8.57

$64.28K

Schimmelpennink Evert B.

27 Mar 2026

President, CEO and Secretary

Buy

28,089

$8.95

$251.41K

George Jeffrey P.

27 Mar 2026

Director

Buy

5,592

$8.92

$49.89K

Olsson Shawn

17 Nov 2025

Chief Commercial Officer

Sold after exercise

5,788

$26.37

$152.61K

Olsson Shawn

17 Nov 2025

Chief Commercial Officer

Sold after exercise

4,212

$25.74

$108.41K

Chevallard Daniel R.

7 Nov 2025

Chief Financial Officer

Buy

2,178

$22.76

$49.56K

Chevallard Daniel R.

7 Nov 2025

Chief Financial Officer

Buy

$22.71

$454.20

MCCOLLUM JAMES W

7 Nov 2025

Director

Buy

10,500

$22.79

$239.28K

Versant Venture Capital VI, L.P.

30 Sep 2025

10% owner

Sell indirect

123

$47.01

$5.78K

Versant Venture Capital VI, L.P.

30 Sep 2025

10% owner

Sell

177

$47.01

$8.32K

Versant Venture Capital VI, L.P.

30 Sep 2025

10% owner

Sell indirect

57,502

$46.41

$2.67M

Versant Venture Capital VI, L.P.

30 Sep 2025

10% owner

Sell

83,066

$46.41

$3.85M

Versant Venture Capital VI, L.P.

30 Sep 2025

10% owner

Sell indirect

34,405

$45.35

$1.56M

Versant Venture Capital VI, L.P.

30 Sep 2025

10% owner

Sell

49,701

$45.35

$2.25M

Versant Venture Capital VI, L.P.

18 Sep 2025

10% owner

Sell indirect

132

$43.30

$5.72K

Versant Venture Capital VI, L.P.

18 Sep 2025

10% owner

Sell

268

$43.30

$11.60K

Versant Venture Capital VI, L.P.

18 Sep 2025

10% owner

Sell indirect

20,148

$43.00

$866.44K

Versant Venture Capital VI, L.P.

18 Sep 2025

10% owner

Sell

40,907

$43.00

$1.76M

Versant Venture Capital VI, L.P.

18 Sep 2025

10% owner

Sell indirect

24,370

$41.59

$1.01M

Versant Venture Capital VI, L.P.

18 Sep 2025

10% owner

Sell

49,479

$41.59

$2.06M

LENZ Therapeutics, Inc.

By person

Individual transactions

What was left out